Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Novavax reports $85M revenue, focuses on cost reduction and partnerships

Novavax's Q3 2024 performance showcased revenue growth and strategic cost reduction efforts.
Key strengths include a strong partnership with Sanofi and a focus on pipeline development.
Challenges ahead involve cost alignment, trial design complexities, and maintaining margins.
Opportunities lie in new pipeline programs, financial gains from partnerships, and cost optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Off and on the price chart, Novavax investors need to be concerned with a mischievous Wall Street bearishly pricing in the news in NVAX stock. The post Novavax Stock Bulls Face an Uphill Challenge appeared first on InvestorPlace.

Novavax Stock Bulls Face an Uphill Challenge

Novavax Stock: Buy, Sell, or Hold in 2022?

Novavax has a lot to look forward to with a surge in Covid-19 cases and a consistent rise in the demand for boosters. Buy NVAX stock.

Novavax Stock Still Has A Solid Chance

It's not too late to invest in this dynamic area.

Which Vaccine Stocks Will Make You a Fortune in 2022?

South Korea has granted approval to the COVID-1i9 vaccine developed by Novavax Inc. NVAX, -3.19% in adults aged 18 and older, the company said Wednesday. The vaccine, known as NVX-CoV2373, is the first protein-based COVID-19 vaccine to be approved for commercial use in South Korea and will be manufactured in the country by SK bioscience.

Novavax' COVID-19 vaccine wins approval in South Korea

GAITHERSBURG, Md., Jan. 12, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and SK bioscience, Co. Limited, a vaccine business subsidiary of Korea-based SK Group, today announced that South Korea's Ministry of Food and Drug Safety (MFDS) has approved a Biologics License Application (BLA) from SK bioscience for Nuvaxovid™ COVID-19 Vaccine (recombinant, adjuvanted) for active immunization in individuals 18 years of age and older for the prevention of COVID-19 caused by SARS-CoV-2.

South Korea Ministry of Food and Drug Safety Approves Novavax COVID-19 Vaccine

Los Angeles, California--(Newsfile Corp. - January 11, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Novavax, Inc. ("Novavax" or "the Company") (NASDAQ: NVAX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Final Deadline Today: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Novavax, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

New York, New York--(Newsfile Corp. - January 11, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Novavax, Inc. (NASDAQ: NVAX) between March 2, 2021 and October 19, 2021, inclusive (the "Class Period"), of the important January 11, 2022 lead plaintiff deadline.SO WHAT: If you purchased Novavax securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees...

NVAX DEADLINE TODAY: ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Novavax, Inc. Investors With Losses Over $100K to Secure Counsel Before Important January 11 Deadline in Securities Class Action - NVAX

NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Novavax, Inc. ("Novavax” or the "Company") (NASDAQ: NVAX) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Novavax between March 2, 2021 and October 19, 2021, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/nvax. This class

NVAX Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Novavax, Inc. Shareholders of Class Action and Lead Deadline: January 11, 2022

The company announced a key regulatory filing for its coronavirus vaccine.

Why Novavax Stock Jumped 6.5% Higher Today

Los Angeles, California--(Newsfile Corp. - January 10, 2022) -  The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Novavax, Inc. ("Novavax" or "the Company") (NASDAQ: NVAX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Deadline Tomorrow Alert: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Novavax, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Novavax, Inc. (NVAX) CEO Stanley Erck Presents at 40th Annual J.P. Morgan Healthcare Conference (Transcript)

The nanoparticle-based vaccine is already available for use in 170 countries, CEO Stanley Erck said.

U.S. Could Authorize Novavax Covid Vaccine—An MRNA Alternative—In February, CEO Says

New York, New York--(Newsfile Corp. - January 10, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Novavax, Inc. (NASDAQ: NVAX) between March 2, 2021 and October 19, 2021, inclusive (the "Class Period"), of the important January 11, 2022 lead plaintiff deadline.SO WHAT: If you purchased Novavax securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or...

NVAX Final Deadline Tomorrow: Rosen, Trusted Investor Counsel, Encourages Novavax, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important January 11 Deadline in Securities Class Action - NVAX

NEW YORK, Jan. 10, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Novavax, Inc. (NASDAQ: NVAX) between March 2, 2021 and October 19, 2021, inclusive (the "Class Period"), of the important January 11, 2022 lead plaintiff deadline. SO WHAT: If you purchased Novavax securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

NVAX FINAL DEADLINE TOMORROW: ROSEN, LEADING INVESTOR COUNSEL, Encourages Novavax, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important January 11 Deadline in Securities Class Action - NVAX

The vaccine-maker expects feedback from American regulators in February.

Novavax CEO says its Covid vaccine could be cleared in multiple countries over next 90 days

Big 5 Sporting Goods

Bakkt Holdings

Cinedigm

CoreCivic

FuboTV

Cassava Sciences Inc

These seven high risk stocks made wild moves in 2021, but still have the potential to rocket higher. All are full of both risk and reward.

7 High Risk Stocks That Are Worth The Volatile Vibes

Novavax has filed for an EUA to distribute Covavax in South Africa. Here's why NVAX stock is rising and could shoot up even higher.

Dear NVAX Stock Fans, You Should Be Watching This Vaccine News

GAITHERSBURG, Md. and PUNE, India, Jan. 10, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Serum Institute of India Pvt.

Novavax and Serum Institute of India File for Emergency Use Authorization of Novavax' COVID-19 Vaccine in South Africa

Boston, Massachusetts--(Newsfile Corp. - January 9, 2022) - The Thornton Law Firm alerts investors that a class action lawsuit has been filed on behalf of investors of Novavax, Inc. (NASDAQ: NVAX). The case is currently in the lead plaintiff stage. Investors who purchased NVAX securities between March 2, 2021 and October 19, 2021 may contact the Thornton Law Firm's investor protection team by visiting www.tenlaw.com/cases/Novavax for more information. Investors may also email investors@tenlaw.com or call...

Thornton Law Firm Reminds Novavax (NVAX) Investors of Securities Class Action

Radnor, Pennsylvania--(Newsfile Corp. - January 9, 2022) - The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that a securities class action lawsuit has been filed against Novavax, Inc. ("Novavax") (NASDAQ: NVAX). The action charges Novavax with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's business, operations, and prospects. As a result of Novavax's materially misleading statements, Novavax investors have suffered significant losses.

Deadline in 2 Days: Kessler Topaz Meltzer & Check, LLP Reminds Novavax, Inc. (NVAX) Investors of Filing Deadline in Class Action Lawsuit and Encourages Investors with Substantial Losses to Contact the Firm

San Diego, California--(Newsfile Corp. - January 8, 2022) -  Robbins Geller Rudman & Dowd LLP announces that purchasers of Novavax, Inc. (NASDAQ: NVAX) securities between March 2, 2021 and October 19, 2021, inclusive ("Class Period") have until this Tuesday, January 11, 2022 to seek appointment as lead plaintiff in Sinnathurai v. Novavax, Inc., No. 21-cv-02910. Filed on November 12, 2021 in the District of Maryland, the Novavax class action lawsuit charges Novavax and its...

TUESDAY DEADLINE: Novavax, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - NVAX

RADNOR, Pa.--(BUSINESS WIRE)---- $NVAX--NVAX DEADLINE: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Novavax, Inc. of Deadline in Securities Fraud Class Action Lawsuit

NVAX DEADLINE: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Novavax, Inc. of Deadline in Securities Fraud Class Action Lawsuit

Pfizer

Vir Biotechnology

These three COVID-19 stocks could rake in a tremendous amount of cash this year.

3 COVID Stocks That Will Make Billions in 2022

Los Angeles, California--(Newsfile Corp. - January 7, 2022) -  The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Novavax, Inc. ("Novavax" or "the Company") (NASDAQ: NVAX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Deadline Tuesday Notice: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Novavax, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

News for Novavax Stock (NVAX)